Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

L'Hôtel-Dieu de Québec
6, rue McMahon
0624
Québec, Québec
Canada G1R 2J6
72 entries « 2 of 8 »

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

Journal Article

Can Urol Assoc J, 2019, ISSN: 1911-6470.

| Links:

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Journal Article

N Engl J Med, 380 (12), pp. 1116-1127, 2019, ISSN: 0028-4793.

Abstract | Links:

Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S

Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling.

Journal Article

BMC Cancer, 19 (1), pp. 137, 2019.

Abstract | Links:

Rouleau M, Lemire F, Dery M, Theriault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guerette D, Pouliot F

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Journal Article

Endocr Connect, 8 (2), pp. 132-140, 2019, ISSN: 2049-3614.

Abstract | Links:

Jain P, Clermont PL, Desmeules F, Zoubeidi A, Neveu B, Pouliot F

Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.

Journal Article

Int J Mol Sci, 20 (1), 2019.

Abstract | Links:

Breau RH, Cagiannos I, Knoll G, Morash C, Cnossen S, Lavallee LT, Mallick R, Finelli A, Jewett M, Leibovich BC, Cook J, LeBel L, Kapoor A, Pouliot F, Izawa J, Rendon R, Fergusson DA

Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol.

Journal Article

BMJ Open, 9 (1), pp. e025662, 2019.

Abstract | Links:

Lavallee E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Journal Article

Eur Urol Focus, 5 (6), pp. 998-1006, 2019.

Abstract | Links:

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond GR, Chua SS, Ho B, Johnston E, Pouliot F, Scott A

Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Journal Article

J Nucl Med, 60 (6), pp. 794-800, 2019, ISSN: 0161-5505.

Abstract | Links:

Metser U, Chua SS, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott A, Tunariu N, Sidhu H, Emmett LM

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy.

Journal Article

J Nucl Med, 60 (9), pp. 1253-1258, 2019, ISSN: 0161-5505.

Abstract | Links:

Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallee LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A

Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.

Journal Article

Urol Oncol, 37 (10), pp. 721-726, 2019, ISSN: 1078-1439.

Abstract | Links:

72 entries « 2 of 8 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Modeling Prostate Cancer in 30 using tissue engineering , Subvention, Association canadienne d'urologie, from 2019-09-11 to 2020-09-10
  • National Program on Radioligand Therapy for Prostate Cancer, Subvention, Cancer de la prostate Canada, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-04-01 to 2021-03-31
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2028-09-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2019-07-01 to 2023-06-30

Recently finished projects

  • Développement et utilisation de systèmes d’amplification transcriptionnelle multigéniques à des fins diagnostiques et thérapeutiques pour améliorer la prise en charge du cancer de la prostate., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2017-07-01 to 2019-06-30
  • Support statistique pour la recherche en Urologie-oncologie, Subvention, Fondation du CHU de Québec, from 2019-03-25 to 2020-03-24
Data provided by the Université Laval research projects registery